Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a
Authors:
Open Access
- 11 May 2020
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 470 (1-2) , 41-51
Abstract
Astragaloside IV (AS/IV) is one of the extracted components from the traditional Chinese medicine Astragalus which has been demonstrated to have potential capacity for anti-inflammation activity and for treating cardiovascular disease. Our purpose was to determine the function and underlying molecular mechanism of AS/IV in hypoxia/reoxygenation (H/R) injured in cardiomyocytes. Differentially expressed genes (DEGs) were screened using bioinformatic analysis, and the molecular targeting relationship was verified by the dual-luciferase report system. H/R injured cardiomyocytes were employed to explore the effect of AS/IV. QRT-PCR and Western blot analysis were applied to detect the expression of mRNA and proteins, respectively. Additionally, superoxide dismutase (SOD), lactic dehydrogenase (LDH) and MDA (malondialdehyde) levels were detected to determine the oxidative damage. Cell viability was assessed by CCK-8, and flow cytometry was used to evaluate cell apoptosis ratio. TGFBR1 and TLR2 were selected as DEGs. Additionally, AS/IV could enhance cell proliferation and upregulated miR-101a expression, which suppressed TGFBR1 and TLR2 expression in H/R injured cardiomyocytes. Moreover, the results of Western blot exhibited that the downstream genes (p-ERK and p-p38) in the MAPK signaling pathway were suppressed, which meant AS/IV could inhibit this pathway in H/R injured cardiomyocytes. Overall, this study demonstrated AS/IV could attenuate H/R injury in human cardiomyocytes via the miR-101a/TGFBR1/TLR2/MAPK signaling pathway axis, which means that it could serve as a possible alternate for H/R treatment.Keywords
This publication has 43 references indexed in Scilit:
- MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-β1 PathwayCirculation, 2012
- Ischaemia-induced up-regulation of Toll-like receptor 2 in circulating monocytes in cardiogenic shockEuropean Heart Journal, 2011
- Toll-Like Receptors: New Players in Myocardial Ischemia/Reperfusion InjuryAntioxidants & Redox Signaling, 2011
- TLR2 Ligand Induces Protection against Cerebral Ischemia/Reperfusion Injury via Activation of Phosphoinositide 3-Kinase/Akt SignalingThe Journal of Immunology, 2011
- Integrin–TGF‐β crosstalk in fibrosis, cancer and wound healingEMBO Reports, 2010
- Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti–Toll-Like Receptor-2 AntibodyCirculation, 2010
- The roles of MAPKs in diseaseCell Research, 2008
- Toll-Like Receptors 2-Deficient Mice Are Protected Against Postischemic Coronary Endothelial DysfunctionArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- A direct interaction between TGFβ activated kinase 1 and the TGFβ type II receptor: Implications for TGFβ signalling and cardiac hypertrophyCardiovascular Research, 2006
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003